Responding to COVID-19.    Read More

Disease Treatments

Factor Deficiency

Factor XIII Deficiency

Understanding Factor XIII Deficiency

Inherited Factor XIII deficiency is the rarest factor deficiency, occurring in 1 out of 5 million births. It is inherited from both parents and affects men and women equally. Acquired forms of Factor XIII deficiency have been reported in association with liver failure, inflammatory bowel disease, and myeloid leukemia.

Symptoms of Factor XIII Deficiency

Symptoms of Factor XIII deficiency include bruise easily, recurrent bleeds including nose and mouth, muscle bleeds, and delayed bleeding after surgery. Umbilical cord bleeding is common in Factor XIII deficiency, found in almost 80% of cases. Up to 30% of patients sustain a spontaneous intracranial hemorrhage, a brain bleed. This is the leading cause of mortality for those with Factor XIII deficiency.1 Females with Factor XIII deficiency who become pregnant have a high risk for miscarriage without appropriate treatment.

Diagnosing Factor XIII Deficiency

Diagnosing Factor XIII Deficiency is made using FXIII assays and a clot solubility test.

Treating Factor XIII Deficiency

Corifact®, manufactured by CSL Behring is prescribed for the treatment of Factor XIII. Corifact is given via intravenous infusion. Tretten®, manufactured by Novo Nordisk, is prescribed for routine prophylaxis in people with congenital Factor XIII A-subunit deficiency.


Contact Nufactor

At Nufactor, we are committed to providing our patients all of the education, support and resources necessary to complete treatment successfully and with the desired outcomes. Please contact us with any further questions.

This content is not intended to substitute professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.